Aerovate Therapeutics Inc

NASDAQ AVTE

Data sourced from iex and EODHD
Download Data

Aerovate Therapeutics Inc Short-Term Investments 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Aerovate Therapeutics Inc Short-Term Investments 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Short-Term Investments are investments that are expected to be converted into cash within a year. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Aerovate Therapeutics Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 92.36 M, a -30.52% change year over year.
  • Aerovate Therapeutics Inc Short-Term Investments for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 132.94 M.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email